Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Neurology · APP-Related Cerebral Amyloid Angiopathy

Standard of Care: Stroke Prevention & Blood Pressure Control

At a Glance

For APP-related amyloidosis, the main way to lower brain-bleed risk is individualized, consistent blood-pressure control, often near 130/80 without causing dizziness or falls. Blood thinners require specialist risk–benefit review, and LAA closure may be an option for some people with AFib.

Because there is currently no cure for APP-related amyloidosis, the primary goal of medical care is risk reduction. Your care team focuses on protecting your brain’s blood vessels, which have become brittle due to the buildup of amyloid-beta [1]. The most important thing you and your doctors can do is strictly manage your blood pressure to prevent a brain bleed (Intracerebral Hemorrhage or ICH) [2][3].

The Gold Standard: Blood Pressure Control

High blood pressure puts immense stress on amyloid-damaged vessels. Research in general CAA and spontaneous hemorrhage populations shows that strict, consistent control of hypertension can reduce the risk of a recurrent brain bleed by as much as 77% [2].

  • The Target: While targets are individualized, experts often consider a blood pressure goal of less than 130/80 mm Hg [2].
  • The Balancing Act: Your doctor will work with you to lower your pressure gradually. It is important to avoid “dips” that are too low, which can cause dizziness or falls—especially since falls carry their own risk of head injury and bleeding [4][5]. Your target must be individualized.
  • Home Monitoring: Checking your blood pressure at home and keeping a log is often more accurate than a single reading in a doctor’s office. This data helps your team adjust your medications safely [2].

The Dilemma of Blood Thinners

For most people, medications like aspirin or “blood thinners” (anticoagulants) are used to prevent strokes. However, for those with APP-related amyloidosis, these drugs pose a significant danger [6].

When amyloid builds up in vessel walls, it creates “microbleeds” and “siderosis” (old blood stains) [7][8]. Blood thinners can turn these tiny leaks into major, life-threatening hemorrhages [9][10].

  • Primary Prevention: Doctors generally advise against taking aspirin or other “antiplatelet” drugs just for general heart health if you have this condition [6].
  • Compelling Reasons: If you have a very high risk of a heart attack or a mechanical heart valve, the decision becomes much more complex and requires a “multidisciplinary” team (neurologists and cardiologists) to weigh the competing risks [11][12]. You should never independently stop or change a prescribed antithrombotic.

Managing Atrial Fibrillation (AFib)

Atrial Fibrillation is a common heart rhythm problem that normally requires blood thinners to prevent clots. For a patient with APP-related amyloidosis, this creates a major medical conflict [12].

If you develop AFib, your team may consider an alternative called Left Atrial Appendage (LAA) Closure (such as the Watchman procedure) [13][5].

  • What it is: A small device is placed in the heart to “plug” the area where most clots form.
  • Why it helps: Once the device is in place and the area has healed, some patients can stop taking long-term blood thinners, lowering their risk of a brain bleed while still being protected from heart-related strokes [14][15].
  • The Catch: You will still need to take a blood thinner or aspirin for a short term immediately after the procedure while the heart heals around the device [14][5]. This is a specialist decision.

Shared Decision Making

Because your condition is rare, your cardiologist or primary care doctor may not be fully aware of the bleeding risks associated with APP mutations. You must be your own advocate:

  1. Share your MRI findings: Specifically mention “microbleeds” and “cortical superficial siderosis,” as these are the red flags for neurologists [7][16].
  2. Ask about DOACs: If a blood thinner is absolutely necessary, Direct Oral Anticoagulants (DOACs) like apixaban are generally considered to have a lower risk of brain bleeding than older drugs like warfarin in the general AFib population, though they are still high-risk for severe CAA patients [17][18].
  3. Prioritize Lifestyle: Beyond medication, stopping smoking and managing cholesterol are important, though they do not have as direct an impact on bleeding risk as blood pressure control does [19][20].
Intervention Benefit Risk/Consideration
BP Control (<130/80) Most effective way to prevent ICH Must avoid dizziness and falls
Blood Thinners Prevents clots/ischemic stroke High Risk for major brain bleed
LAA Closure Alternatives to thinners in AFib Requires short-term thinners after surgery
Lifestyle (No Smoking) General vascular health Less impact on amyloid-specific bleeding

Common questions in this guide

What blood pressure goal is often considered for APP-related amyloidosis?
Clinicians often consider a goal below 130/80 mm Hg, but the right target depends on your health and should be individualized. Blood pressure should be lowered carefully enough to avoid dizziness, falls, or other problems from pressure that is too low. Home readings and a blood pressure log can help your care team adjust treatment safely.
Should I take aspirin or a blood thinner if I have APP-related amyloidosis?
Aspirin or other blood-thinning medicines are generally not recommended solely for general heart-health prevention in people with this condition because fragile brain vessels may bleed. If you have a strong medical reason, such as atrial fibrillation or a mechanical heart valve, neurologists and cardiologists should weigh the clotting and bleeding risks together. Never stop or change a prescribed blood thinner without medical guidance.
Why can blood thinners be dangerous with APP-related amyloidosis?
Amyloid can weaken brain-vessel walls and is associated with small bleeds and cortical superficial siderosis. Antiplatelet medicines and anticoagulants can allow these leaks to become a major intracerebral hemorrhage. The level of risk depends on your MRI findings and other health factors.
What are the options if I develop atrial fibrillation?
Atrial fibrillation often raises the need for stroke-preventing anticoagulation, which can be difficult when brain-bleed risk is high. A specialist team may consider left atrial appendage closure, such as a Watchman procedure, for selected patients. Short-term blood-thinning treatment or aspirin is usually still needed while the device heals into place.
Which MRI findings should I tell my doctors about?
Tell every relevant clinician about cerebral microbleeds and cortical superficial siderosis on your MRI because these findings can signal a higher risk of brain bleeding. Sharing the MRI report or diagnosis is especially important with cardiologists, emergency clinicians, and anyone considering antiplatelet or anticoagulant treatment.
Can lifestyle changes lower my risk of complications?
Not smoking and managing cholesterol support overall blood-vessel health, but consistent blood pressure control has the most direct role in reducing intracerebral hemorrhage risk in this setting. Keeping a home blood pressure log and reporting dizziness or lightheadedness can also make treatment safer.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on APP-related brain and vascular amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my specific target blood pressure, and how often should I be monitoring it at home to ensure we are meeting that goal?
  2. 2.Given my MRI findings (like microbleeds or siderosis), how do you weigh the risks versus benefits of any antiplatelet or anticoagulant medications I might need for other conditions?
  3. 3.If I develop an irregular heartbeat like Atrial Fibrillation, are you comfortable referring me to a cardiologist who has experience with Left Atrial Appendage (LAA) closure for CAA patients?
  4. 4.What is the protocol if I am ever admitted to an emergency room for a suspected stroke? How can we ensure they don't give me clot-busting drugs (tPA) without checking for my specific condition?
  5. 5.Are there specific blood pressure medications you prefer for my condition that might also help protect my brain's blood vessels?

References

References (20)
  1. 1

    Phenotype and imaging features associated with APP duplications.

    Grangeon L, Charbonnier C, Zarea A, et al.

    Alzheimer's research & therapy 2023; (15(1)):93 doi:10.1186/s13195-023-01172-2.

    PMID: 37170141
  2. 2

    Cerebral Amyloid Angiopathy in Stroke Medicine.

    Block F, Dafotakis M

    Deutsches Arzteblatt international 2017; (114(3)):37-42.

    PMID: 28179050
  3. 3

    Cerebral amyloid angiopathy: diagnosis and potential therapies.

    Weber SA, Patel RK, Lutsep HL

    Expert review of neurotherapeutics 2018; (18(6)):503-513 doi:10.1080/14737175.2018.1480938.

    PMID: 29792540
  4. 4

    Blood Pressure and Outcomes in Patients With Different Etiologies of Intracerebral Hemorrhage: A Multicenter Cohort Study.

    Zhang S, Wang Z, Zheng A, et al.

    Journal of the American Heart Association 2020; (9(19)):e016766 doi:10.1161/JAHA.120.016766.

    PMID: 32924756
  5. 5

    Left Atrial Appendage Closure for Patients with Cerebral Amyloid Angiopathy and Atrial Fibrillation: the LAA-CAA Cohort.

    Schrag M, Mac Grory B, Nackenoff A, et al.

    Translational stroke research 2021; (12(2)):259-265 doi:10.1007/s12975-020-00838-5.

    PMID: 32770310
  6. 6

    Antithrombotic therapy in patients with cerebral microbleeds.

    Wilson D, Werring DJ

    Current opinion in neurology 2017; (30(1)):38-47 doi:10.1097/WCO.0000000000000411.

    PMID: 27898582
  7. 7

    Convexity subarachnoid hemorrhage in lobar intracerebral hemorrhage: A prognostic marker.

    Raposo N, Charidimou A, Roongpiboonsopit D, et al.

    Neurology 2020; (94(9)):e968-e977 doi:10.1212/WNL.0000000000009036.

    PMID: 32019785
  8. 8

    Cortical superficial siderosis predicts early recurrent lobar hemorrhage.

    Roongpiboonsopit D, Charidimou A, William CM, et al.

    Neurology 2016; (87(18)):1863-1870 doi:10.1212/WNL.0000000000003281.

    PMID: 27694268
  9. 9

    Cerebral Amyloid Angiopathy Imaging Markers, Radiological Boston Criteria, and Thrombolysis Outcomes in Ischemic Stroke.

    Marzoughi S, Alhabli I, Singh N, et al.

    Stroke 2026; (57(4)):933-944 doi:10.1161/STROKEAHA.125.054654.

    PMID: 41608814
  10. 10

    Transient Focal Neurological Events in Cerebral Amyloid Angiopathy and the Long-term Risk of Intracerebral Hemorrhage and Death: A Systematic Review and Meta-analysis.

    Sanchez-Caro JM, de Lorenzo Martínez de Ubago I, de Celis Ruiz E, et al.

    JAMA neurology 2022; (79(1)):38-47 doi:10.1001/jamaneurol.2021.3989.

    PMID: 34779831
  11. 11

    New horizons: managing antithrombotic dilemmas in patients with cerebral amyloid angiopathy.

    Kelly J

    Age and ageing 2021; (50(2)):347-355 doi:10.1093/ageing/afaa275.

    PMID: 33480964
  12. 12

    The growing clinical spectrum of cerebral amyloid angiopathy.

    Wermer MJH, Greenberg SM

    Current opinion in neurology 2018; (31(1)):28-35 doi:10.1097/WCO.0000000000000510.

    PMID: 29120920
  13. 13

    Percutaneous left atrial appendage closure: beyond the classic indications.

    Guérios EE, Chamié F

    AsiaIntervention 2023; (9(1)):70-77 doi:10.4244/AIJ-D-22-00040.

    PMID: 36936101
  14. 14

    Left atrial appendage occlusion in patients with atrial fibrillation and intracerebral haemorrhage associated with cerebral amyloid angiopathy: a multicentre observational study and pooled analysis of published studies.

    Thiankhaw K, Best J, Srivastava S, et al.

    Journal of neurology, neurosurgery, and psychiatry 2025; (96(6)):528-536 doi:10.1136/jnnp-2024-334718.

    PMID: 39694822
  15. 15

    Atrial fibrillation and coexisting cerebral amyloid angiopathy: safety and efficacy of transcatheter left atrial appendage occlusion.

    Gurgoglione FL, Barocelli F, Solinas E, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2026; (47(5)).

    PMID: 42020825
  16. 16

    The Clinical Dilemma of Anticoagulation Use in Patients with Cerebral Amyloid Angiopathy and Atrial Fibrillation.

    Cannistraro RJ, Meschia JF

    Current cardiology reports 2018; (20(11)):106 doi:10.1007/s11886-018-1052-1.

    PMID: 30209626
  17. 17

    Cerebral haemorrhage in the patient with atrial fibrillation: do we employ the direct oral anticoagulants without waiting too long?

    Vassiliki' Coutsoumbas G, Di Pasquale G

    European heart journal supplements : journal of the European Society of Cardiology 2024; (26(Suppl 1)):i64-i68 doi:10.1093/eurheartjsupp/suae020.

    PMID: 38867877
  18. 18

    [Intracerebral hemorrhage under platelet inhibition and oral anticoagulation in patients with cerebral amyloid angiopathy].

    Haußmann R, Homeyer P, Haußmann M, et al.

    Der Nervenarzt 2022; (93(6)):599-604 doi:10.1007/s00115-021-01206-w.

    PMID: 34652485
  19. 19

    Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer's disease.

    Inoue Y, Shue F, Bu G, Kanekiyo T

    Molecular neurodegeneration 2023; (18(1)):46 doi:10.1186/s13024-023-00640-5.

    PMID: 37434208
  20. 20

    The Impact of Vascular Risk Factors on Cerebral Amyloid Angiopathy: A Cohort Study in Hereditary Cerebral Amyloid Angiopathy and a Systemic Review in Sporadic Cerebral Amyloid Angiopathy.

    Voigt S, Voigt S, Rasing I, et al.

    Cerebrovascular diseases (Basel, Switzerland) 2025; (54(5)):746-760 doi:10.1159/000542666.

    PMID: 39557031

This page is for informational purposes only and does not constitute medical advice. Blood-pressure, blood-thinner, and left atrial appendage closure decisions for APP-related amyloidosis must be individualized with your treating clinicians; do not stop a prescribed medication on your own.